USA flag logo/image

An Official Website of the United States Government

Profiling EGFR and Her2 in Breast Cancer using Multiplex Tissue Immunostaining

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85395
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
CA123994
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
20/20 GENESYSTEMS, INC.
9430 Key West Ave. Suite 100 ROCKVILLE, MD 20850-6347
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Profiling EGFR and Her2 in Breast Cancer using Multiplex Tissue Immunostaining
Agency: HHS
Contract: 1R43CA123994-01A2
Award Amount: $117,930.00
 

Abstract:

DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies, including Herceptin(r) and novel tyrosine kinase inhibitors. 20/20 will utilize its proprietary layered peptide array (LPA) technology. Transfer of antibody probes from a single tissue section to numerous bioaffinity me mbranes permits multiple target antigens (up to 50 if needed) to be assessed in a quantitative manner while preserving the local spatial orientation of the targets relative to the tissue section. The immediate goals are to develop a panel of 7 assays (comp rising antigen-coated membranes and relevant antibodies), and to demonstrate their use for profiling AKT signaling in cultured breast cancer cells and archival tissues. During Phase II, we will demonstrate its tissue applications with animal models, and wi th human breast tissue sections from clinical trials in breast cancer patients treated with growth factor and Akt inhibitors. The product would have utility in both a research and clinical laboratory setting. Importantly, the system is open-ended to the ad dition of new prognostic markers and drug targets into the assay panel. There are several anticipated advantages of the layered membrane platform over current histopathology tools such as immunohistochemistry (IHC). These include conservation of tissue (su ch as for core needle biopsies) and the ability to simultaneously profile multiple signaling proteins in both normal and phosphorylated form. Our options for breast cancer diagnosis and treatment will increasingly take advantage of information obtained fro m tumor profiling assays, which will indicate customized therapies for each form of the disease. The novel diagnostic techniques to be researched will allow for microscopic profiling of tiny amounts of tissue for numerous cancer-causing molecules. There wi ll be applications in pre-clinical studies and drug trials, which will aim to invent novel treatment strategies using combinations of drugs that block 'growth factor' molecules.

Principal Investigator:

William M. James
3014357882
BJAMES@2020GENE.COM

Business Contact:

Jonathan Cohen
gtroy@202gene.com
Small Business Information at Submission:

20/20 GENESYSTEMS, INC.
20/20 GENESYSTEMS, INC. 9700 GREAT SENECA HWY ROCKVILLE, MD 20850

EIN/Tax ID: 522272107
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No